The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts forecast ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended December 2024. While this widely-known consensus ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVS Health (CVS – Research Report) and ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

BioMarin Pharmaceutical, a global biotechnology company, sports a Zacks Rank #1 and a VGM Score of B. BMRN has a trailing four-quarter earnings surprise of 28.7%, on average. You can see the ...